Effects of Open-Label Atomoxetine on African-American and Caucasian Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Data on the management of attention-deficit/hyperactivity disorder (ADHD) in African-American children and adolescents are limited. Methods: This study sought to evaluate the tolerability, safety, and efficacy of atomoxetine hydrochloride in the management of ADHD in African-American children and adolescents by conducting a post hoc subgroup analysis of 2 multicenter, open-label studies. Results: Atomoxetine was safe and well tolerated, with ≥3.0% of African-Americans and Caucasians discontinuing treatment because of adverse events. A significantly higher proportion of Caucasians reported ≥1 treatment-emergent adverse event, including vomiting (7.2% vs 1.2%; P = .037) and fatigue (6.1% vs 0%; P = .012). No serious safety concerns were observed. Changes from baseline in height, weight, and hemodynamic variables were modest and similar in both racial subgroups. African-Americans and Caucasians showed significant improvement from baseline to end point in the mean ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-P:I). Scores decreased by 20.1 in African-Americans and by 19.55 in Caucasians, without significant between-group differences. Patients in both racial groups experienced similar, significant improvements in ADHDRS-IV-P:I inattention and hyperactivity-impulsivity symptoms, Clinical Global Impression-ADHD-Severity, and Conners’ Parent Rating Scale-Revised: Short Form. Conclusions: Atomoxetine exhibited similar tolerability, safety, and efficacy profiles in African-Americans and Caucasians with ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 1×
“Atomoxetine has been demonstrated to be effective, safe, and well tolerated in children and adolescents 20-22 and adults 23,24 with ADHD.”
National trends in the treatment of attention deficit hyperactivity disorder
Olfson, M., Gameroff, M. J., Marcus, S. C., & Jensen, P. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1071 · Cited by 394
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
Barriers to detection, help-seeking, and service use for children with ADHD symptoms
Bussing, R., Zima, B. T., Gary, F. A., & Garvan, C. W. (2003) · The Journal of Behavioral Health Services & Research · doi:10.1007/bf02289806 · Cited by 303
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00006 · Cited by 191
Remission versus response as the goal of therapy in ADHD: A new standard for the field?
Steele, M., Jensen, P. S., & Quinn, D. M. P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.006 · Cited by 174 · cited 1×
“33 The present study included remission after atomoxetine treatment as an efficacy end point: an ADHDRS-IV-P:I total T-score ≤60 or a CGI-ADHD-S score ≤2 at study end point.”
Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD
Arnold, L. E., Elliott, M., Sachs, L., Bird, H., Kraemer, H. C., Wells, K. C., Abikoff, H. B., Comarda, A., Conners, C. K., Elliott, G. R., et al. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.713 · Cited by 159
Cited by
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Durell, T. M., Adler, L. A., Williams, D. W., Deldar, A., McGough, J. J., Glaser, P. E., Rubin, R. L., Pigott, T. A., Sarkis, E. H., & Fox, B. K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827d8a23 · Cited by 64
“Previous analyses of atomoxetine treatment in children across racial/ethnic categories found no significant differences in efficacy or tolerability.(39,40) Nonetheless, the underrepresentation of minorities in this trial is consistent with a broader problem of the difficulties in minority recruitment in clinical trial…”
ResultSelf-citationToward Quality Care in ADHD: Defining the Goals of Treatment
Rostain, A., Jensen, P. S., Connor, D. F., Miesle, L. M., & Faraone, S. V. (2015) · Journal of Attention Disorders · doi:10.1177/1087054712473835 · Cited by 33
Metadata
- Authors
- Durell, T. M., Pumariega, A. J., Rothe, E. M., Tamayo, J. M., Baron, D., & Williams, D.
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2009-02
- Volume
- 21
- Issue
- 1
- Pages
- 26-37
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W94022314
- Cited by
- 19
- References
- 10
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Open-Label Atomoxetine on African-American and Caucasian Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1177/104012370902100104
- The paper
- Durell, T. M., Pumariega, A. J., Rothe, E. M., Tamayo, J. M., Baron, D., & Williams, D. (2009). Effects of Open-Label Atomoxetine on African-American and Caucasian Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder. Annals of Clinical Psychiatry. https://doi.org/10.1177/104012370902100104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.